GMT is written as "GREENWICH MEAN TIME", the omega replica Royal Greenwich Observatory in hublot replica London, England, focusing on replica watch uk the word "GMT" that symbolizes the pursuit of human civilization for the accuracy of time.Albert refers to the first generation of swiss rolex replica GMT no shoulder pads, gold ring on the surface, and black gold (glossy gilt) is more soft. Interview GMT-MASTER Ref. 1675 for the fake watches uk GMT-MASTER third generation, especially the addition of round mouth shoulder pads, the market value of about 72,000 yuan.

Innovate UK Funding Award for Locate Therapeutics and The University of Nottingham

11th Feb 2016
NOTTINGHAM, 11th February 2016 – Locate Therapeutics Ltd (“Locate”), the regenerative medicine development company, and the School of Pharmacy at The University of Nottingham, have been awarded a grant from Innovate UK, the UK’s innovation agency, to jointly adapt the company’s TAOS™ technology (Targeted, Orchestrated Signaling Matrix) for use in administering therapeutic cells.

Emerging cell therapies have vast potential in the treatment of currently incurable diseases; the potential market for cell-based therapies being over 100 million patients in the US alone. Some of the main targets include heart disease, diabetes, neurodegenerative diseases, musculoskeletal disorders, spinal cord injury, stroke, autoimmune diseases and trauma.

The partners believe that a current barrier to success is the inefficient clinical administration of these therapies to the patient. Under-developed methods for presenting the cells can result in the majority of the therapy dying or migrating away soon after injection.

The funding award aims to redress this issue by creating purpose-built delivery vehicles that provide protective environments and solidify upon injection, with the aim of improving the survival, localisation, and clinical effectiveness of cell therapies.

Dr Robin Quirk, Chief Executive of Locate, commented: "Our TAOS advanced delivery matrix is proving itself to be a highly versatile technology. With this funding, we aim to demonstrate its potential as a delivery substrate to improve the clinical administration of cell therapies across both hard and soft tissue applications. With the University of Nottingham as a development partner, we will be well supported in this endeavour. We’re excited by the potential of this product in a variety of clinical scenarios”.

Dr Susan Huxtable, Director of Intellectual Property and Commercialisation at The University of Nottingham, added: “It is very good news that Locate has been given this award from Innovate UK. Locate is developing new and innovative technologies with great commercial potential, and this funding will help them to further advance their work”.

For further information please email info@locatetherapeutics.com or call +44 (0)115 784 0041.

Product Development Pipeline
Application Development
Partnering Opportunities

© 2014 Locate Therapeutics Limited.

All rights reserved.

Registered in England number 04202562.

Locate Therapeutics Limited

MediCity

Thane Road

Beeston

Nottingham NG90 6BH

United Kingdom

 

+44 (0)115 784 0041

info@locatetherapeutics.com